Atrimustine
| Atrimustine | |
|---|---|
| |
| INN | |
| Drug class | Chemotherapeutic agent; Estrogen; Estrogen ester |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 75219-46-4 |
| PubChem | 6917688 |
| DrugBank | |
| ChemSpider | 5292918 |
| KEGG | |
Atrimustine (INN
) (developmental code name KM-2210; former tentative brand name Kregan), also known as bestrabucil or busramustine, is a cytostatic antineoplastic agent which was under development in Japan by Kureha Chemicals (now Kureha Corporation) for the treatment of breast cancer and non-Hodgkin's lymphoma as well as for the prevention of graft-versus-host disease in bone marrow transplant recipients.[1][2][3] It is the benzoate ester of an ester conjugate of estradiol and chlorambucil,[4] which results in targeted/site-directed cytostatic activity toward estrogen receptor-positive tissues such as breast and bone.[5][6] It reached preregistration for the treatment of cancer but was ultimately discontinued.[3] Estrogenicic side effects of atrimustine in clinical trials included vaginal bleeding and gynecomastia.[3] The drug was first patented in 1980.[1]
See also[edit | edit source]
References[edit | edit source]
- ↑ 1.0 1.1 {{{last}}}, J. Elks, The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. online version, Springer, ISBN 978-1-4757-2085-3, Pages: 897–898,
- ↑ {{{last}}}, William Andrew Publishing, Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. online version, Elsevier, ISBN 978-0-8155-1856-3, Pages: 438–,
- ↑ 3.0 3.1 3.2 https://adisinsight.springer.com/drugs/800000756
- ↑ , The Cancer Bulletin. online version, Medical Arts Publishing Foundation, 1987,
- ↑ , [Bestrabacil: a possible target-oriented anticancer agent], Gan to Kagaku Ryoho, 1984, Vol. 11(Issue: 10), pp. 2115–24, PMID: 6548354,
- ↑ {{{last}}}, Joji Ishigami, Recent Advances in Chemotherapy: Proceedings of the 14th Internat. Congress of Chemotherapy, Kyoto, 1985. Antimicrobial section; 1. 1 ,1. online version, University of Tokyo Press, 1985, ISBN 978-0-86008-385-6,
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
